Search Result

Results for "

performance

" in MCE Product Catalog:

By Targets:	Adenylate Cyclase (2) Amyloid-β (1) Antibiotic (1) Apoptosis (1) Biochemical Assay Reagents (2) Cholinesterase (ChE) (2) Dopamine Receptor (2) Dopamine Transporter (2) EAAT2 (1) EGFR (1) Endogenous Metabolite (3) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Fungal (1) GABA Receptor (2) iGluR (2) Isotope-Labeled Compounds (2) Melatonin Receptor (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) nAChR (1) Sigma Receptor (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Infection (2) Metabolic Disease (1) Neurological Disease (15)

By Targets:

Adenylate Cyclase (2)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (1)

Biochemical Assay Reagents (2)

Cholinesterase (ChE) (2)

Dopamine Receptor (2)

Dopamine Transporter (2)

EAAT2 (1)

EGFR (1)

Endogenous Metabolite (3)

Estrogen Receptor/ERR (1)

Fluorescent Dye (1)

Fungal (1)

GABA Receptor (2)

iGluR (2)

Isotope-Labeled Compounds (2)

Melatonin Receptor (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

nAChR (1)

Sigma Receptor (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (2)

Infection (2)

Metabolic Disease (1)

Neurological Disease (15)

Inhibitors & Agonists

Fluorescent Dye

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-100782

DL-AP7 2-APH; 2-Amino-7-phosphonoheptanoic acid	iGluR	Neurological Disease
DL-AP7 is a competitive NMDA antagonist and an anticonvulsant. DL-AP7 blocks the NMDA-induced convulsions and impairs learning performance in a passive avoidance task in mice.

HY-151951

Antidepressant agent 4	GABA Receptor Melatonin Receptor Sigma Receptor	Neurological Disease
Antidepressant agent 4 is an orally active antidepressant agent. Antidepressant agent 4 exhibits antidepressant, anxiolytic, performance enhancing and nootropic activities.

HY-151950

Antidepressant agent 3	GABA Receptor Melatonin Receptor Sigma Receptor	Neurological Disease
Antidepressant agent 3 is an orally active antidepressant agent. Antidepressant agent 3 exhibits antidepressant, anxiolytic, performance enhancing and nootropic activities.

HY-149975

AMPA receptor modulator-4	iGluR	Neurological Disease
AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulators of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice.

HY-B1124A

Fipexide hydrochloride	Adenylate Cyclase Dopamine Transporter	Neurological Disease
Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is a nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research.

HY-B1124

Fipexide	Adenylate Cyclase Dopamine Transporter	Neurological Disease
Fipexide, a parachloro-phenossiacetic acid derivative, is a nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research.

HY-109121

Reldesemtiv CK-2127107	Others	Cardiovascular Disease
Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC₅₀ of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model.

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety.

HY-144660

AChE-IN-7	Cholinesterase (ChE)	Neurological Disease
AChE-IN-7 (Compound 16) is a selective and potent inhibitor of acetylcholinesterase (eeAChE IC₅₀ = 0.045 μM; eeBuChE IC₅₀ = 19.68 μM). AChE-IN-7 is safe in vivo and in vitro, and shows good overall pharmacokinetic performance and high bioavailability (F = 55.5%). AChE-IN-7 also has high BBB permeability.

HY-15344

(R,R)-BD-AcAc 2 (R,R)-Ketone Ester	Others	Metabolic Disease Neurological Disease
(R,R)-BD-AcAc 2 ((R,R)-Ketone Ester), a ketone monoester, can be used as a source of oral nutritional ketones. (R,R)-BD-AcAc 2 can elevate plasma levels of β-hydroxybutyrate and acetoacetate, blood glucose, blood Na⁺ levels and blood creatinine levels after oral administration in mice. (R,R)-BD-AcAc 2 can partly prevent muscle weakness in septic mice. (R,R)-BD-AcAc 2 has potential to improve exercise performance and endurance in animal body. (R,R)-BD-AcAc 2 can also be used to research Parkinson’s disease or diabetes.

HY-N6070

Ricinoleic acid	Biochemical Assay Reagents	Others
Ricinoleic acid, a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings.

HY-A0272

Sodium laureth sulfate Sodium lauryl polyoxyethylene ether sulfate	Others	Others
Sodium lauryl polyoxyethylene ether sulfate is an anionic surfactant, with excellent decontamination, emulsification, dispersion, wetting, solubilizing performance and foaming property.

HY-N6070A

Ricinoleic acid (purity≥99%)	Biochemical Assay Reagents	Others
Ricinoleic acid (purity≥99%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings.

HY-16675

7-Epi-10-oxo-docetaxel Docetaxel Impurity 2	Microtubule/Tubulin	Cancer
7-Epi-10-oxo-docetaxel (Docetaxel Impurity 2) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

HY-17578

Pneumocandin B0 L-688786	Fungal Antibiotic	Infection
Pneumocandin B0(L-688786), a key intermediate in the synthesis of the antifungal agent, Cancidas, has led to the identification of several materials with potential for improved performance.

HY-100511

Benzophenonetetracarboxylic acid 3,3',4,4'-Benzophenonetetracarboxylic acid	Others	Others
Benzophenonetetracarboxylic acid (3,3',4,4'-Benzophenonetetracarboxylic acid) is particularly useful in the preparation of high performance polyimides and also useful as curing agents for epoxy resins.

HY-W018161

Hexadecanedioic acid	Endogenous Metabolite	Others
Hexadecanedioic acid is covalently linked to Sepharose 4B, shows better performance in terms of specificity than dye-based resins and could be used for depletion of SA from plasma samples.

HY-135737

Dicaprylyl carbonate	Others	Others
Dicaprylyl carbonate, a solid, plant-derived fat, is a dry emollient. Dicaprylyl carbonate has excellent dermatological compatibility and a comprehensive performance profile, such as solubilizing and dispersing ability for sun-care filters.

HY-100784

Dihydrokainic acid	EAAT2	Neurological Disease
Dihydrokainic acid (DHK) is a glutamate transporter GLT1 (EAAT2) inhibitor. Dihydrokainic acid impairs novel object recognition (NOR) memory performance in mice. Dihydrokainic acid also shows epileptogenic effects.

HY-W027544

MCA	Fluorescent Dye	Others
MCA is a coumarin derivative. MCA quantitates platelet-activating factor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities.

HY-W018161S

Hexadecanedioic acid-d28	Endogenous Metabolite	Others
Hexadecanedioic acid-d₂₈ is the deuterium labeled Hexadecanedioic acid. Hexadecanedioic acid is covalently linked to Sepharose 4B, shows better performance in terms of specificity than dye-based resins and could be used for depletion of SA from plasma samples.

HY-P99216

Ponezumab PF-04360365; RN 1219	EGFR	Neurological Disease
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.

HY-N3383

Ligustroside Ligstroside	Mitochondrial Metabolism	Neurological Disease
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages.

HY-103374

Phenserine (-)-Eseroline phenylcarbamate; (-)-Phenserine	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease.

HY-144314

PSDalpha	Estrogen Receptor/ERR	Cancer
PSDalpha is an ERα degrader conjugating photosensitizer (PS), triphenylamine benzothiadiazole (TB) and 17β-estradiol via an acetylene bond. PSDalpha shows excellent anti-proliferation performance on MCF-7 cells. The maximum absorption wavelength of PSDalpha in the visible region is located at 465 nm.

HY-W008610

GBR 12783	Dopamine Receptor	Neurological Disease
GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats.

HY-100968

GBR 12783 dihydrochloride	Dopamine Receptor	Neurological Disease
GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats.

HY-101415

Coenzyme Q9 Ubiquinone Q9; CoQ9; Ubiquinone 9	Apoptosis Endogenous Metabolite	Cardiovascular Disease
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis.

HY-W027544S

(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d3 7-Methoxy-d3-2-oxo-2H-1-benzopyran-4-acetic acid; 7-Methoxy-d3-2H-chromen-2-one-4-acetic acid	Isotope-Labeled Compounds	Others
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d₃ is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activating factor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3].

HY-W027544S1

(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6 5-(Dimethyl-d6-amino)-N-(prop-2-ynyl)naphthalene-1-sulfonamide	Isotope-Labeled Compounds	Others
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d₆ is the deuterium labeled MCA[1]. MCA is a coumarin derivative. MCA quantitates platelet-activating factor by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities[2][3].

Cat. No.	Product Name	Type